Table 1 Baseline patient characteristics

From: Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

Patient characteristic

Number of patients (%)

Total number of patients

57

Female

21 (37)

Male

36 (63)

Mean age at diagnosis (years)

53.7

Mean age at treatment (years)

57.4

Site of primary tumour

Small bowel

20 (35)

Pancreas

15 (26)

Lung

2 (3.5)

Colon

1 (1.7)

Appendix

4 (7)

Stomach

1 (1.7)

Liver

1 (1.7)

Unknown

13 (23)

Site of metastasis

Liver

53 (93)

Lymph nodes

16 (28)

Lung

4 (7)

Bone

11 (19)

Ovarian

2 (3.5)

Peritoneal

1 (1.7)

Presenting symptom

Diarrhoea

27 (47)

Flushing

31 (54)

Abdominal pain

17 (30)

Weight loss

10 (17.5)

Fatigue/tiredness

9 (16)

Breathlessness

5 (9)

Sweats

5 (9)

Vomiting

3 (5)

Hypoglycaemia

1 (1.7)

Jaundice

1 (1.7)

Dizziness

1 (1.7)

Anxiety

1 (1.7)

Previous treatment

Small bowel resection

11 (19)

Hemicolectomy

6 (10.5)

Pancreatic resection

4 (7)

Stenting/bypass

4 (7)

Somatostatin analogues

33 (58)

Chemotherapy

10 (17.5)

Interferon-α

6 (10.5)

Hepatic chemoembolisation

3 (5)

Radiotherapy

1 (1.7)